OneAscent Financial Services LLC Purchases 13,278 Shares of Bristol Myers Squibb Company (NYSE:BMY)

OneAscent Financial Services LLC grew its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 115.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,790 shares of the biopharmaceutical company's stock after purchasing an additional 13,278 shares during the quarter. OneAscent Financial Services LLC's holdings in Bristol Myers Squibb were worth $1,496,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. CBIZ Investment Advisory Services LLC lifted its holdings in Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 231 shares during the period. Counterweight Ventures LLC lifted its holdings in Bristol Myers Squibb by 2.5% during the first quarter. Counterweight Ventures LLC now owns 20,702 shares of the biopharmaceutical company's stock worth $1,263,000 after acquiring an additional 499 shares during the period. Elyxium Wealth LLC bought a new stake in Bristol Myers Squibb during the first quarter worth $256,000. Berkeley Capital Partners LLC lifted its holdings in Bristol Myers Squibb by 0.6% during the first quarter. Berkeley Capital Partners LLC now owns 44,767 shares of the biopharmaceutical company's stock worth $2,730,000 after acquiring an additional 271 shares during the period. Finally, South Dakota Investment Council lifted its holdings in Bristol Myers Squibb by 0.9% during the first quarter. South Dakota Investment Council now owns 431,279 shares of the biopharmaceutical company's stock worth $26,304,000 after acquiring an additional 3,787 shares during the period. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $47.40 on Monday. Bristol Myers Squibb Company has a 52 week low of $41.90 and a 52 week high of $63.33. The business has a 50-day simple moving average of $47.47 and a 200 day simple moving average of $52.89. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The stock has a market cap of $96.46 billion, a price-to-earnings ratio of 17.75, a PEG ratio of 2.48 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the previous year, the business earned ($4.40) earnings per share. The firm's revenue was down 5.6% on a year-over-year basis. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.23%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is 92.88%.

Insider Buying and Selling

In other news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president directly owned 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.07% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Jefferies Financial Group dropped their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Morgan Stanley decreased their target price on Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating for the company in a research report on Thursday, July 10th. Finally, Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and an average price target of $57.69.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.